Lyell Immunopharma, Inc. (LYEL)

Market Cap	159.78M
Revenue (ttm)	61,000
Net Income (ttm)	-342.99M
Shares Out	295.23M
EPS (ttm)	-1.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	608,817
Open	0.5905
Previous Close	0.5936
Day's Range	0.5365 - 0.6118
52-Week Range	0.4810 - 3.1450
Beta	-0.42
Analysts	Sell
Price Target	1.00 (+84.78%)
Earnings Date	Mar 11, 2025

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi‑R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: LYEL
• Website: https://www.lyell.com

Financial Performance

In 2024, Lyell Immunopharma's revenue was $61,000, a decrease of -53.08% compared to the previous year's $130,000. Losses were -$342.99 million, 46.2% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for LYEL stock is "Sell." The 12-month stock price forecast is $1.0, which is an increase of 84.78% from the latest price.

Price Target

$1.0

(84.78% upside)

Analyst Consensus: Sell